8.65
Schlusskurs vom Vortag:
$8.52
Offen:
$8.49
24-Stunden-Volumen:
3.89M
Relative Volume:
0.88
Marktkapitalisierung:
$1.81B
Einnahmen:
$503.49M
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-33.27
EPS:
-0.26
Netto-Cashflow:
$-26.89M
1W Leistung:
-0.80%
1M Leistung:
-14.36%
6M Leistung:
+13.52%
1J Leistung:
+16.58%
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BCRX
Biocryst Pharmaceuticals Inc
|
8.65 | 1.82B | 503.49M | -53.47M | -26.89M | -0.26 |
![]()
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
2025-02-25 | Eingeleitet | Wedbush | Outperform |
2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
2023-02-22 | Hochstufung | Needham | Hold → Buy |
2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-03-01 | Eingeleitet | Cowen | Outperform |
2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
2020-06-17 | Eingeleitet | BTIG Research | Neutral |
2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2017-12-20 | Eingeleitet | Barclays | Equal Weight |
2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2016-02-09 | Bestätigt | FBR Capital | Outperform |
2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewswire
Is BioCryst Pharmaceuticals Inc. a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com
What analysts say about BioCryst Pharmaceuticals Inc. stockFree Stock Selection - Autocar Professional
BioCryst: ORLADEYO Powers Profitability Amidst Rising HAE Competition (NASDAQ:BCRX) - Seeking Alpha
BioCryst Pharmaceuticals to Announce Q2 2025 Financial Results and Host Conference Call on August 4, 2025 - Quiver Quantitative
BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastFree Wealth Management Insights - printweek.in
What drives BioCryst Pharmaceuticals Inc. stock priceFree Capital Efficiency Planning - Autocar Professional
How To Trade (BCRX) - news.stocktradersdaily.com
BioCryst appoints Babar Ghias as CFO - MSN
Will BioCryst Pharmaceuticals Inc. stock benefit from AI tech trendsCarefully Curated High Return Stocks - beatles.ru
BioCryst Pharmaceuticals (BCRX) Rallies 1.28% Amid Analyst Coverage - AInvest
AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies - GlobeNewswire Inc.
Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB - The Globe and Mail
RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - MSN
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit - GlobeNewswire
BioCryst Unveils Groundbreaking Research on HAE Treatment Burden in Young Patients Under 12 - Stock Titan
Island Pharmaceuticals announces purchase of Galidesivir antiviral program from Biocryst Pharmaceuticals - MarketScreener
Island Pharmaceuticals acquires BioCryst’s Galidesivir - grafa.com
BioCryst Pharmaceuticals appoints Babar Ghias as CFO By Investing.com - Investing.com South Africa
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - GlobeNewswire
Island Pharmaceuticals Acquires Galidesivir Antiviral Program from BioCryst Pharmaceuticals - AInvest
CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com
Missed PDUFA history as Kalvista wins FDA approval for HAE - BioWorld MedTech
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? - Yahoo
BioCryst Pharmaceuticals (BCRX) Appoints New CFO, Babar Ghias - GuruFocus
BioCryst Pharmaceuticals Appoints Babar Ghias as Chief Financial Officer and Head of Corporate Development - Quiver Quantitative
BioCryst Pharmaceuticals appoints Babar Ghias as CFO - Investing.com
BioCryst Taps Dealmaking Powerhouse as New CFO: $80B Transaction Expert to Drive Growth Strategy - Stock Titan
BioCryst Pharmaceuticals shares rise 1.37% after-hours following the appointment of Babar Ghias as CFO. - AInvest
BioCryst Appoints Babar Ghias Chief Financial Officer and Head o - GuruFocus
BioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264M - Insider Monkey
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Expands Team with 57,000 Share RSU Package: Latest Details on New Hiring Spree - Stock Titan
BioCryst Pharma (BCRX) Receives Boost with Increased Price Target | BCRX Stock News - GuruFocus
BioCryst Pharma (BCRX) Maintains Outperform Rating and $13 Price Target | BCRX Stock News - GuruFocus
BCRX Stock Rating and Price Target Update by Wedbush | BCRX Stoc - GuruFocus
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):